1-20 of 65
Peter A Riedell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BsAbs before CD19 CAR-T: full speed ahead!

Peter A. Riedell
Journal: Blood
Blood (2024) 144 (3): 249–251.
https://doi.org/10.1182/blood.2024025048
Published: 2024
Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Clinical Trials & Observations
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez-Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thieblemont, Stephen J. Schuster
Journal: Blood
Blood (2024) 143 (17): 1713–1725.
https://doi.org/10.1182/blood.2023021567
Published: 2024
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood
Blood (2023) 142 (Supplement 1): 617.
https://doi.org/10.1182/blood-2023-184862
Published: 2023
Journal Articles

Combination of Ibrutinib with CD19 Chimeric Antigen Receptor (CAR) T Cells Suggests Greater Contribution to CAR T-Cell Efficacy Than Other Approved BTK Inhibitors in the Preclinical Setting

Vicki Plaks, Vidusha Cyril, Peter A Riedell, Qianqian Zhao, Jason Hall, Joel Tan, Diala Harb, Matthew S Davids
Journal: Blood
Blood (2023) 142 (Supplement 1): 2817.
https://doi.org/10.1182/blood-2023-181805
Published: 2023
Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 894.
https://doi.org/10.1182/blood-2023-174510
Published: 2023
Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy
Journal: Blood
Blood (2023) 142 (Supplement 1): 2110.
https://doi.org/10.1182/blood-2023-186570
Published: 2023
Journal Articles

Longitudinal Patient-Reported Outcomes (PROs) in a Prospective Registry of CAR T-Cell Therapy Recipients

Ajay Major, Thomas Althaus, Benjamin Brewer, Sarah Schmiege, Justin Kline, Michael R. Bishop, Jamie L Studts, Paul Cook, Peter A. Riedell
Journal: Blood
Blood (2023) 142 (Supplement 1): 2387.
https://doi.org/10.1182/blood-2023-178398
Published: 2023
Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Marie José Kersten, Umar Farooq, Aaron P. Rapoport, Frederick L. Locke, Lori A. Leslie, Armin Ghobadi, David B. Miklos, Caron A. Jacobson, Javier L. Munoz, Patrick B Johnston, Samantha M. Jaglowski, Ian W. Flinn, Tom van Meerten, Miguel-Angel Perales, Peter Vandenberghe, Peter A. Riedell, Kathleen Dorritie, David Szwajcer, Dimitrios Tzachanis, Saran Vardhanabhuti, Linqiu Du, Simone Filosto, Shilpa A. Shahani, Christina To, Jason Westin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1761.
https://doi.org/10.1182/blood-2023-173873
Published: 2023
Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Alison R Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon
Journal: Blood
Blood (2023) 142 (Supplement 1): 105.
https://doi.org/10.1182/blood-2023-180952
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Tanya Siddiqi, David G Maloney, Saad S. Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 330.
https://doi.org/10.1182/blood-2023-179529
Published: 2023
Journal Articles

Accelerating the Adoption of New and Emerging Therapies for DLBCL: A Community-Based Quality Improvement Initiative

Peter A. Riedell, Ellie Moses-Okwei, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen
Journal: Blood
Blood (2023) 142 (Supplement 1): 7264.
https://doi.org/10.1182/blood-2023-173686
Published: 2023
Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Stephen J Schuster, Nathan Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A Riedell, Phoebe Joy Ho, Jose A. Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers Patten, Joseph P McGuirk, Andreas L Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Ines Paule, Davide Germano, Roberto Javier Ramos, Pei Hsu, Catherine Thieblemont, Martin Dreyling
Journal: Blood
Blood (2023) 142 (Supplement 1): 601.
https://doi.org/10.1182/blood-2023-180936
Published: 2023
Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Alexandra E. Rojek, Peter A. Riedell, Farrukh T. Awan, Laura Samples, Mazyar Shadman, Marie Hu, Veronika Bachanova, William Wesson, Nausheen Ahmed, Madiha Iqbal, Mohamed A. Kharfan-Dabaja, Michael Scordo, Patrick Connor Johnson, Yi-Bin Chen, Sawa Ito, Mehdi Hamadani, Matthew J. Frigault
Journal: Blood
Blood (2023) 142 (Supplement 1): 3088.
https://doi.org/10.1182/blood-2023-184345
Published: 2023
Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault
Journal: Blood
Blood (2023) 142 (Supplement 1): 3496.
https://doi.org/10.1182/blood-2023-179387
Published: 2023
Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Austin I Kim, Philippe Armand, Robert A. Redd, Megan Forsyth, Paul Branch, Samantha Pazienza, Lisa Brennan, Victoria Patterson, Susan M Waisgerber, Reid W. Merryman, David C Fisher, Christine E. Ryan, Inhye E Ahn, Jennifer L Crombie, Oreofe O. Odejide, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, Matthew S Davids, Jennifer R. Brown, Arnold S. Freedman, Peter A. Riedell, Mark Alan Murakami
Journal: Blood
Blood (2023) 142 (Supplement 1): 3031.
https://doi.org/10.1182/blood-2023-173103
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Yazeed Sawalha, Shayna R Sarosiek, Rina Li Welkie, Sherif Seif, Shrinjaya Thapa, Saurabh Zanwar, Kirk Cahill, Rachel Treitman, Haikoo Shah, Shagun Arora, Georgios Pongas, Allison Winter, Ajay Major, Peter A. Riedell, Maria Lia Palomba, Prashant Kapoor, Ariel F. Grajales-Cruz, Kenneth H. Shain, Sheeba K. Thomas, Jorge J. Castillo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3045.
https://doi.org/10.1182/blood-2023-187237
Published: 2023
Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed
Journal: Blood
Blood (2023) 142 (Supplement 1): 4887.
https://doi.org/10.1182/blood-2023-182837
Published: 2023
Journal Articles

Targeting BCMA in Plasmablastic Lymphoma: Two Cases of Therapeutic Response to Teclistamab

Joseph Cannova, Adam S. Duvall, Girish Venkataraman, Geoffrey D. Wool, Sandeep Gurbuxani, Peter A. Riedell
Journal: Blood
Blood (2023) 142 (Supplement 1): 6282.
https://doi.org/10.1182/blood-2023-190814
Published: 2023
Journal Articles

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Mazyar Shadman, Matthew J Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini
Journal: Blood
Blood (2023) 142 (Supplement 1): 3497.
https://doi.org/10.1182/blood-2023-180233
Published: 2023
Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Roni Shouval, Christopher Strouse, Soyoung Kim, Temitope Oloyede, Sairah Ahmed, Farrukh T. Awan, Veronika Bachanova, Talha Badar, Pere Barba, Amer M. Beitinjaneh, Amanda F Cashen, Bhagirathbhai Dholaria, Mahmoud Elsawy, Siddhartha Ganguly, Praveen Ramakrishnan Geethakumari, Uri Greenbaum, Hamza Hashmi, Laquisa C. Hill, Michael D. Jain, Tania Jain, Partow Kebriaei, Adam S Kittai, Frederick L. Locke, Premal D. Lulla, Elena Mead, Joseph P McGuirk, Alberto Mussetti, Taiga Nishihori, Amanda L. Olson, Martina Pennisi, Miguel-Angel Perales, Peter A. Riedell, Wael Saber, Sayeef Mirza, Margarida Magalhaes-Silverman, Elizabeth J. Shpall, Mohamed Sorror, Kitsada Wudhikarn, Cameron J. Turtle, Marcelo Pasquini, Amy Moskop
Journal: Blood
Blood (2023) 142 (Supplement 1): 355.
https://doi.org/10.1182/blood-2023-181181
Published: 2023